Exhibit 99.1 ASX ANNOUNCEMENT 12 January 2026 ───────────────────────────────────────── EBR Announces Strong Q4 FY2025 Commercial and Clinical Progress Key Highlights Strong commercial momentum continued through Q4 2025 with case volumes doubling from Q3 2025 ─────────────────────────────────────────────────────────────────────────────────── The WiSE® System was successfully implanted in 18 commercial patients during the quarter, reaching 30 implants for the combined pilot phase and Limited Market Release ──────────────────────────────────────────────────────────────────────────────────────────────────── EBR expects to report revenue in the range of US$870K and US$935K for Q4 2025, and total 2025 revenue in the range of US$1,552K and $1,617K, based on preliminary unaudited year-end results and subject to year-end closing adjustments The Limited Market Release continued to advance in Q4 with an incremental 9 purchase agreements signed and 11 additional physicians trained to support the adoption of WiSE ───────────────────────────────────────────────────────────────────────────────────────────────────── WiSE-UP post-approval study commenced, wit…
Open exhibit ↗Current Report · Items 2.02, 9.01 · 8-K
EBR Systems, Inc.
EBRCZOTCEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On January 12, 2026, EBR Systems, Inc. (the “Company”) issued a press release announcing the Company’s commercial and clinical progress, as well as preliminary financial results for the fourth quarter and year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report.…
Press release in this filing
EBR Announces Strong Q4 FY2025 Commercial and Clinical Progress Key Highlights →Company context
Silicon Valley-based EBR Systems (ASX:EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.